OPKO Health, Inc. — Form 8-K Summary
Reporting context: The 8-K reports an event determined on October 1, 2026, following the quarter ended September 30, 2026. It concerns the company’s 3.75% Convertible Senior Notes due 2029, not quarterly financial results.
Key financial and capital structure information
- Approximately $121 million of principal remains outstanding on the Notes.
- The company elected to satisfy conversion obligations in shares of common stock.
- For each $1,000 principal amount converted, holders receive 869.5652 common shares plus any additional shares applicable under the Indenture’s early-conversion provisions. The filing does not quantify the total potential shares.
- The filing provides no revenue, earnings, cash flow, margin, or liquidity figures.
Material development
Holders may convert the Notes through December 31, 2026. The conversion right was triggered after OPKO’s closing share price exceeded $1.495—130% of the $1.15 applicable conversion price—for at least 20 of 30 consecutive trading days during the quarter ended September 30, 2026. The Notes may become convertible again after December 31 if a conversion condition in the Indenture is met in a future measurement period.
Outlook, risks, and contingencies
Conversions may result in additional common shares being issued and dilution to existing shareholders; the amount depends on conversions and the applicable early-conversion terms. The filing gives no estimate of conversion activity or resulting dilution. Conversion procedures and complete terms are governed by the Indenture, with U.S. Bank Trust Company, National Association serving as trustee and conversion agent.
Investor verification points
- Review the Indenture dated January 9, 2024, for conversion mechanics and early-conversion provisions.
- Verify the principal amount converted and shares issued as holders exercise their rights.
- Check whether conversion conditions are met in future measurement periods and whether conversion rights continue after December 31, 2026.